Synaptogenix (NASDAQ:TAOX) Stock Price Down 10.4% – What’s Next?

Shares of Synaptogenix, Inc. (NASDAQ:TAOX) traded down 10.4% during mid-day trading on Friday . The company traded as low as $3.29 and last traded at $3.29. 130,224 shares changed hands during trading, an increase of 51% from the average daily volume of 86,513 shares. The stock had previously closed at $3.67.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TAOX shares. Wall Street Zen upgraded Synaptogenix from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Synaptogenix Stock Performance

The company has a market capitalization of $24.58 million, a P/E ratio of -0.25 and a beta of 1.42. The firm’s fifty day moving average is $3.88 and its 200 day moving average is $4.58.

Synaptogenix (NASDAQ:TAOX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $0.43 earnings per share (EPS) for the quarter. The firm had revenue of $5.96 million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.